FDA Approved: EVISTA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for Evista to expand its labeling. The update adds a use for reducing breast cancer risk in postmenopausal women at incr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• Evista (raloxifene)

Snippet

SUPPL AP for EVISTA (RALOXIFENE HYDROCHLORIDE)